Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05594290 | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery(MERCURY) | active not recruiting | Phase 2 | 36 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06232564 | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs(PELICAN) | active not recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 |
| Jan 14, 2026 |
| clinicaltrials |
| NCT06573723 | Institutional Registry of Rare Diseases | recruiting | — | 380 | Hospital Italiano de Buenos AiresOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05353257 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | active not recruiting | Phase 3 | 511 | Shanghai Henlius BiotechINDUSTRY | 11 | Jan 13, 2026 | clinicaltrials |
| NCT05735912 | EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)(ERASIN-RCT) | active not recruiting | N/A | 60 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06406387 | ATRX/DAXX in EUS-FNB Specimens of Pan-NETs(FORESEE) | active not recruiting | — | 100 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07335679 | Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma(CCSTR) | recruiting | — | 60 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337447 | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)(REWENEC 01) | not yet recruiting | Phase 2 | 122 | Hospices Civils de LyonOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06663072 | Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 25 | University of ChicagoOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06936813 | The PROMISE Survey | active not recruiting | — | 530 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06282016 | Risk Factors for Neuroendocrine Neoplasms | recruiting | — | 14,250 | Bavarian Cancer RegistryOTHER_GOV | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT06584123 | Molecular Pituitary Imaging Using 18F-FET PET(FET-pit-PET) | recruiting | N/A | 20 | University of CambridgeOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer(DeLLphi-304) | active not recruiting | Phase 3 | 509 | AmgenINDUSTRY | 31 | Jan 5, 2026 | clinicaltrials |
| NCT05978284 | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 54 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07038096 | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 350 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07189455 | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 420 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07314255 | The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma(ZL2025) | active not recruiting | — | 60 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07141264 | Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy | recruiting | Phase 2 | 32 | Tang-Du HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07309211 | Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT | recruiting | — | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07102056 | 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms | not yet recruiting | — | 152 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07308379 | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer | not yet recruiting | — | 1,200 | Fudan UniversityOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07302100 | Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital(DENUTNE) | recruiting | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03691064 | Post-Authorization Long-Term Safety Study of LUTATHERA(SALUS) | active not recruiting | — | 1,014 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT07299318 | Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer | not yet recruiting | — | 3,200 | West China HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07272512 | Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms(ZSPAC-17) | recruiting | Phase 4 | 350 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05450965 | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | recruiting | Phase 2 | 37 | University of Maryland, BaltimoreOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) | active not recruiting | Phase 3 | 563 | AmgenINDUSTRY | 29 | Dec 17, 2025 | clinicaltrials |
| NCT06926634 | Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) | recruiting | Phase 2 | 32 | Washington University School of MedicineOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289048 | A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT07279532 | Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06758700 | Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06623578 | Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC | recruiting | N/A | 876 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07175077 | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) | recruiting | — | 20 | University of Missouri-ColumbiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04624477 | Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | active not recruiting | — | 450 | University Health Network, TorontoOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT05178693 | Lutathera and ASTX727 in Neuroendocrine Tumours(LANTana) | recruiting | Phase 1 | 27 | Imperial College LondonOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 14, 2026source: clinicaltrials